Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $27.2 million.

  • Inhibikase Therapeutics' Gains from Investment Securities rose 873843.38% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 873843.38%. This contributed to the annual value of $1.4 million for FY2020, which is N/A changed from last year.
  • Per Inhibikase Therapeutics' latest filing, its Gains from Investment Securities stood at $27.2 million for Q3 2025, which was up 873843.38% from $25.8 million recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Gains from Investment Securities high stood at $27.2 million for Q3 2025, and its period low was $18039.0 during Q1 2024.
  • For the 5-year period, Inhibikase Therapeutics' Gains from Investment Securities averaged around $4.7 million, with its median value being $86669.0 (2023).
  • As far as peak fluctuations go, Inhibikase Therapeutics' Gains from Investment Securities tumbled by 9677.94% in 2021, and later surged by 11813934.25% in 2025.
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Gains from Investment Securities stood at $29839.0 in 2021, then soared by 156.88% to $76651.0 in 2022, then rose by 13.07% to $86669.0 in 2023, then skyrocketed by 255.42% to $308039.0 in 2024, then soared by 8738.43% to $27.2 million in 2025.
  • Its last three reported values are $27.2 million in Q3 2025, $25.8 million for Q2 2025, and $21.3 million during Q1 2025.